Category Archives: Genetics

The comparative and genetic methods for East European …

Taxonomy of freshwater mussels from family Unionidae has been ambiguous for a long time. A number of methods used for their identification, including the so-called comparative method, are based on shell morphology. However, this morphology turned out to have a high level of within-species variation, and the shape of the shell of a specimen depends strongly on its environment and conditions of growth. For these reasons, the number of species recognized by the comparative method kept increasing. We applied both the comparative morphological method and methods of molecular genetics to address the taxonomy of Unionidae. We performed the comprehensive study of 70 specimens of Unionidae mussels collected from the River Ivitza, Volga basin. The specimens represented 14 comparative species, belonging to 4 comparative genera of Unionidae: Colletopterum, Pseudanodonta, Unio and Crassiana. Sequencing of the nuclear (ITS1) and mitochondrial (COI, 16S rDNA) genetic regions revealed 5 groups with high within-group genetic homogeneity separated from each other by long genetic distances. According to the comparison with the available sequences, these groups correspond to 3 Eastern European genera and 5 species: Anodonta anatina, Pseudanodonta complanata, Unio pictorum, Unio tumidus and Unio crassus. The results obtained indicate that the comparative method is inappropriate for the taxonomic analysis of East European Unionidae.

More:
The comparative and genetic methods for East European ...

Analysts See $-0.13 EPS for Cancer Genetics, Inc. (CGIX …

August 13, 2018 - By Kristin Houston

Investors sentiment increased to 1.11 in Q1 2018. Its up 0.20, from 0.91 in 2017Q4. It improved, as 3 investors sold Cancer Genetics, Inc. shares while 6 reduced holdings. 6 funds opened positions while 4 raised stakes. 2.70 million shares or 2.75% less from 2.78 million shares in 2017Q4 were reported.The Illinois-based Northern Tru Corporation has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Morgan Stanley holds 16,169 shares or 0% of its portfolio. Geode Limited Liability has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). 11,600 were accumulated by Spark Invest Management Ltd Llc. Perkins Cap Management reported 963,600 shares. Virtu Financial Ltd Liability Corporation accumulated 0% or 29,495 shares. Granahan Inv Ma owns 235,502 shares. Wells Fargo Mn reported 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). National Bank Of America Corporation De has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Barclays Public Limited Company has invested 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). Moreover, Jacobs Levy Equity Management Incorporated has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). The New York-based Hrt Lc has invested 0.02% in Cancer Genetics, Inc. (NASDAQ:CGIX). Vanguard Group Inc holds 583,886 shares or 0% of its portfolio. Dimensional Fund Advsr Limited Partnership reported 19,866 shares. Diker Mngmt Ltd Liability invested 0.04% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX).

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.13 EPS on August, 14 before the open.They anticipate $0.03 EPS change or 18.75 % from last quarters $-0.16 EPS. After having $-0.16 EPS previously, Cancer Genetics, Inc.s analysts see -18.75 % EPS growth. The stock decreased 3.22% or $0.0314 during the last trading session, reaching $0.9451. About 69,965 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 74.25% since August 13, 2017 and is downtrending. It has underperformed by 86.82% the S&P500.

Among 2 analysts covering Cancer Genetics (NASDAQ:CGIX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cancer Genetics had 3 analyst reports since April 3, 2018 according to SRatingsIntel. The firm earned Hold rating on Tuesday, April 3 by Maxim Group. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has Buy rating given on Tuesday, May 29 by H.C. Wainwright. The company was maintained on Wednesday, June 27 by H.C. Wainwright.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $26.22 million. The Companys tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

More news for Cancer Genetics, Inc. (NASDAQ:CGIX) were recently published by: Nasdaq.com, which released: Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018 on August 07, 2018. Globenewswire.coms article titled: Cancer Genetics Closes $2.625 million Convertible Note Financing and published on July 18, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:
Analysts See $-0.13 EPS for Cancer Genetics, Inc. (CGIX ...

Atossa Genetics Announces Second Quarter 2018 Financial …

SEATTLE, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced second quarter ended June 30, 2018 financial results and provided an update on recent company developments.

Steve Quay, President and CEO commented, We have made tremendous progress with our clinical programs. We opened enrollment in two phase 2 clinical studies: one study using our proprietary topical Endoxifen for breast density reduction, and another study using our proprietary oral Endoxifen for reducing breast cancer tumor cell activity in the window of opportunity between diagnosis of breast cancer and surgery. We also completed dosing and patient visits in our phase 1 study of topical Endoxifen in men. Our intraductal microcatheter immunoOncology pre-clinical program was launched and we contracted with an additional manufacturer for Endoxifen. We have had a very busy and productive first six months of 2018 as we continue the momentum in the advancement of our clinical programs. We are looking forward to announcing preliminary results from our phase 1 study of topical Endoxifen in men by September 30, 2018, added Dr. Quay.

Recent Corporate Developments

Atossas important recent developments include the following:

Q2 2018 Financial Results

For the three and six months ended June 30, 2018 and 2017, we had no revenue and no associated cost of revenue.

Total operating expenses were approximately $4.1 million and $6.0 million for the three and six months ended June 30, 2018, respectively, consisting of general and administrative (G&A) expenses of approximately $2.7 million and $4.1 million, respectively; and research and development (R&D) expenses of approximately $1.5 million and $1.9 million, respectively. For the previous year, total operating expenses were approximately $1.9 million and $3.6 million for the three and six months ended June 30, 2017, respectively, consisting of G&A expense of approximately $1.1 million and $2.2 million, respectively, and R&D expenses of $0.8 million and $1.4 million, respectively.

About Atossa Genetics

Atossa Genetics Inc., is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit http://www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossas drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.Kyle GuseCFO and General CounselOffice: 866 893-4927kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott GordonCorProminence LLC377 Oak StreetConcourse 2Garden City, NY 11530Office: (516) 222-2560scottg@corprominence.com

Source: Atossa Genetics Inc.

Read more:
Atossa Genetics Announces Second Quarter 2018 Financial ...

Understanding genetic architecture of different traits and …

ByRobin Scullin

Scientists at Johns Hopkins Bloomberg School of Public Health have developed a powerful method for characterizing patterns of genetic contributions to different traits such as height, BMI, and childhood IQ, as well as diseases including Alzheimer's disease, diabetes, heart disease, and bipolar disorder. The new method provides a "big picture" of genetic influences that should be particularly helpful in designing future genetic studies and understanding genetic risk prediction.

In a study published today in the journal Nature Genetics, the scientists mined existing data from genetic studies and used novel statistical techniques to obtain estimates of the numbers of DNA variations that contribute to different physical traits and diseases,

"In terms of practical results, we can now use this method to estimate, for any trait or disease, the number of individuals we need to sample in future studies to identify the majority of the important genetic contributions," says study senior author Nilanjan Chatterjee, a Bloomberg Distinguished Professor in the Department of Biostatistics.

Bloomberg Distinguished Professor in Department of Biostatistics

Affordable DNA-sequencing technology became available around the turn of the millennium. With it, researchers have performed hundreds of genome-wide association studies to discover DNA variations that are linked to different diseases or traits. These variationscalled single nucleotide polymorphisms, or SNPsare changes in DNA "letters" at various sites on the genome. Knowing which variations are linked to a disease or trait can be useful in gaining biological understanding about how diseases and other traits originate and further progress.

There is also interest in using genetic markers to develop risk-scores that could identify individuals at high or low risk for diseases and then use the information to develop a "precision medicine" approach to disease prevention.

"Depending on their sample sizes, previous genome-wide association studies have uncovered a few SNPs or many for any given disease or trait," Chatterjee says. "But what they generally haven't done is reveal the overall genetic architectures of diseases or traitsin other words, the likely number of SNPs that contribute and the distributions of their effect sizes."

Chatterjee and his colleagues developed statistical tools to infer this overall architecture from publicly available genome-wide association study data. They then applied these tools to 32 datasets covering 19 quantitative traits and 13 diseases.

The findings show that what is known about many traits represents the "tip of the iceberg." An individual trait could be associated with thousands to tens of thousands of SNPs, each of which has small effect, but which cumulatively make a substantial contribution to the trait variation. Intriguingly, they found that traits related to mental health and ability, such as IQ, depression, and schizophrenia, appear to be influenced by the largest number, on the order of tens of thousands of SNPs, each with tiny effects.

"For the traits we analyzed related to mental health and cognitive ability, there is really a continuum of effect sizes, suggesting a distinct type of genetic architecture," says Chatterjee, who has a joint appointment in Johns Hopkins Medicine's Department of Oncology.

By contrast, the analysis suggested that common chronic diseases such as heart disease and type-2 diabetes typically are influenced by relatively feweron the order of thousandsof SNPs, most of which have small effects, although a sizable group "stick out" for their stronger effects.

Knowing the approximate genetic architecture of a disease or trait allows scientists to predict how informative any new genome-wide association studies for that trait or disease will be, given the sample size. For example, projections in the study suggest that for most traits and diseases, such as heart disease and diabetes, the point of diminishing return for these studies only starts after a sample size reaches several hundred thousand. For psychiatric diseases and cognitive traits, with their "long-tail" distributions of gene effects, diminishing returns usually won't kick in until sample sizes are even larger‐possibly in the millions, Chatterjee says. These results have implications for how useful genetic risk prediction models could be for different diseases depending on the sample size achievable for future studies.

"Our approach at least provides the best available 'road map' of what is needed in future studies," Chatterjee says.

See the original post here:
Understanding genetic architecture of different traits and ...

Basic Genetics

Learn.Genetics visitors,

Were asking for your help. For over 20 years, the Learn.Genetics website has provided engaging, multimedia educational materials at no cost.

Learn.Genetics is one of the most-used science websites. Tens of millions of visitors come to our site each year to find the science and health information theyre looking for.

If Learn.Genetics is useful to you, please take a moment to donate even a few dollars from each of our visitors would add up to a significant amount!

Your support will help us keep Learn.Genetics free and available to everyone. It will also help us develop new content for you.

Please help us keep Learn.Genetics going!

Thank you, The Genetic Science Learning Center team creators of Learn.Genetics

See the original post here:
Basic Genetics

Genetics Nurse | Discover Nursing

A Genetics Nurse helps patients with or at risk for diseases related to their genetics, diseases like cancer, heart disease, diabetes, and Alzheimers. These nurses perform risk assessments and analyze the data found. A career in Genetics Nursing can be very rewarding, youll help patients and families better prepare themselves for the potentially harmful diseases that run in their family.

The rest is here:
Genetics Nurse | Discover Nursing

Genetics and Human Genetics | Graduate School

The Department of Genetics and Human Genetics offers courses leading to the Master of Science and Doctor of Philosophy degrees . The program is associated with the Departments of Pediatrics and Biology so that students will not only learn to work creatively in their own field of special interest but will also be able to relate their findings to progress made in related disciplines.

The graduate programs in Genetics & Human Genetics are designed to confer the training standards that will develop students for degrees of Doctorate of Philosophy Masters, and M.D./Ph.D. degree(s). The graduate program is an interdepartmental entity built on a diverse platform.

The program is associated with the department of Pediatrics and department of Biology where students work creatively in their field of special interest but and be able to relate application and relevance to related clinical and science disciplines.

The degree programs are designed to provide a curricular foundation in human genetics for all enrolled students during their first year.Following this, guided by their academic adviser, students elect to pursue their area of interest in genetics . This is accomplished through a combination of elective courses offered in the Department and other departments of the University, as well as in the Washington Area Consortium of Universities. The Masters thesis and Doctoral dissertation research interests likewise can reflect a broad range of interests, provided a suitable research mentor is identified in the graduate faculty.

This training program design takes into account the fact that genetics is increasingly relevant within the framework of multiple biomedical research and scholarly pursuits. The program design also is intended to foster the important principle of collaborative research and scholarship among biomedical disiplines.

The graduate programs are research-oriented curriculum's in the study of genetic mechanisms related to the transition from normal to disease states and intended to prepare graduates to participate in laboratory research.

To be accepted into the Graduate Program in Genetics and Human Genetics, students must have a Bachelors degree from an accredited institution and a GPA of at least 3.0 or B equivalent. In addition, students must meet the University requirement(s) to take the Graduate Record Examination (and the TOEFL if applicable).

Students with a bachelor degree may enter the graduate program at the Masters level or directly into the Ph.D. program. Eligibility to be considered for direct admission as a Ph.D. student requires a cumulative GPA greater than 3.2 and prior research and/or training experience in during undergraduate school or during a previous Masters degree

Applicants are required to submit these items for consideration of acceptance and review of potential for success:

Students wishing to enter the master's program should have a baccalaureate degree and a cumulative GPA average of B or the equivalent. They also should have completed undergraduate courses in modern biology, chemistry through organic chemistry, general biochemistry, mathematics through calculus, and general genetics, or equivalent courses. These prerequisites apply regardless of specialization selected within the master's program.

Students with less than a B average or who have not completed all of the required undergraduate courses may be admitted conditionally if they have very high Graduate Record Examination scores and/or excellent recommendations.

Students may matriculate into the doctoral program, having completed a suitable Masters degree, provided they present evidence of previous research experience supported by excellent letters of recommendation, and grades above 3.2 average.

Students who do not meet these general criteria may be considered for the master's program as indicated above.

The degree programs are designed to provide a curricular foundation in human genetics during their first and second year. Following years students elect to pursue elective courses in their area of interest.

Classes for degree credits are gained through a combination of elective courses offered in the Department, other departments within the University, and from courses offered through the Washington Area Consortium of Universities.

To confer the degree of Masters in Science requires;

To confer the degree of Doctor of Philosophy requires;

The College of Medicine and the Graduate School jointly offer an integrated program that leads to both the M.D. and Ph.D. degrees without compromise in the customary substance of each of these degrees individually. Additionally, the curricular emphasis develops in the trainee the unique professional role perspective of the clinician/scientist/scholar. It also develops a particular appreciation for the urgent and unsolved health problems that are present in the population served by the Howard University Hospital and its affiliated clinical programs.

Application Process

Graduate departments that currently invite applications for Ph.D. study in this program are: Anatomy, Biochemistry and Molecular Biology, Biology, Chemistry, Communication Sciences and Disorders, Genetics and Human Genetics, Microbiology, Pharmacology, Physiology and Biophysics.

The steps in the application process are as follows:

The application for the M.D./Ph.D. program shou ld be returned to:

Kareem Washington, Ph.D.Director M.D./Ph.D. ProgramHoward University College of Medicine520 W Street, NWWashington, DC 20059email:kareem.washington @howard.edu

A student, with the advice of the director of graduate studies, may file for admission to candidacy.

Students in the Ph.D. program are required to spend at least three semesters in full-time residence, two of which must be consecutive.

See original here:
Genetics and Human Genetics | Graduate School

Good Start Genetics

Thank you for visiting Goodstartgenetics.com. Good Start has been acquired by Invitae.

As of June 25, 2018, carrier screening is available to order through Invitae. If youre looking to access an order status placed prior to June 25, 2018, please login to your Gateway account.

Invitae Preimplantation Genetic Testing (PGT) ordering and order status is still available through your Gateway account.

Please visit Invitae to learn more about reproductive health testing for your patients.

If your doctor has ordered carrier screening for you prior to June 25, 2018, you may access your results and payment options by visiting the PersonalVu patient portal. For new patients, please log in to the Invitae patient portal to view your results and order status.

If your doctor has ordered preimplantation genetic testing for you, please log into the PersonalVu patient portal to watch our educational video, sign your informed consent and pay your bill.

Please visit Invitae to learn more about our reproductive health testing options.

For any additional questions, please contact Invitae.

Original post:
Good Start Genetics

Genetics – jobs.ac.uk

Applications are invited for a Research Assistant post in bioinformatics. The successful applicant will join a multi-disciplinary team studying virus comparative genomics, gene expression, evolution, taxonomy, RNA structure and function, and novel virus discovery. The position will be based in the laboratory of Dr Andrew Firth in the...

Originally posted here:
Genetics - jobs.ac.uk

Seattle Genetics’ Latest Approval Is the Best Yet — The …

Seattle Genetics (NASDAQ:SGEN) saw salesof its only approved drug Adcetris jump substantially in the second quarter, thanks to the Food and Drug Administration approval for the frontline treatment of stage III and IV Hodgkin lymphoma, which was granted in the first quarter.

Metric

Q2 2018

Q2 2017

Year-Over-Year Change

Revenue

$170.2 million

$108.2 million

57%

Income from operations

($30.3 million)

($59.3 million)

N/A

Earnings per share

$0.47

($0.39)

N/A

Data source: Seattle Genetics.

Image source: Getty Images.

"This is the highest sequential quarter-to-quarter growth rate since the product was launched," said Darren Cline, Seattle Genetics' executive vice president of commercial, which shows how big the approval for frontline Hodgkin lymphoma was for the company.

Nevertheless, CEO Clay Siegall cautioned investors that the initial increase in usage might not continue at the same rate:

It takes time to build market share in a setting where the standard of care hasn't changed in 40 years. I mean, it just takes time, and we are off to a good start. Our commercial team was ready. They were ready. They jumped on this, and we got the rapid adopters in. But the rest of the time, we're going to be making stepwise moves up there.

Management is guiding for third-quarter Adcetris sales in the range of $130million to $135million, a 6.2% to 10.3% quarter-over-quarter increase.

The next growth opportunity for Adcetris will come from mature T-cell lymphoma in a clinical trial called Echelon-2, which is scheduled to read out early in the fourth quarter. The number of potential patients with mature T-cell lymphoma is about the same as frontline Hodgkin lymphoma, but the current treatment isn't particularly good. So it may be easier to get rapid adoption in mature T-cell lymphoma if the Echelon-2 results show Adcetris is substantially better than the current standard of care.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Go here to see the original:
Seattle Genetics' Latest Approval Is the Best Yet -- The ...